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Large-cell neuroendocrine carcinoma (LCNEC) of the gallbladder is extremely rare. We present a 63-year-old Chinese
female who was admitted with right upper quadrant pain and a quasi-circular tumor measuring 2.0 cm on the
body of the gallbladder, as indicated by computed tomography. LCNEC combined with adenocarcinoma was
immunohistochemically confirmed after open radical cholecystectomy. Postoperative recovery of this patient was
uneventful, and no evidence of recurrence or metastasis was observed after 12 months of follow-up. LCNEC of
the gallbladder is thought to be extremely rare and is usually found in combination with other histological carcinoma
types, such as adenocarcinoma, as determined histologically. The prognosis is poor overall, but early detection with
complete resection may result in a relatively good prognosis.
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Neuroendocrine neoplasms (NENs) account for 1.25% of
all malignancies, with the majority (66%) occurring in
the gastrointestinal tract, followed by the bronchopul-
monary system (31%). Other less frequent locations in-
clude the ovaries, testes, pancreas, and hepatobiliary
system. Gallbladder NENs are particularly rare, and 278
cases were registered in the Surveillance, Epidemiology
and End Results (SEER) from 1973 to 2005, only repre-
senting 0.5% of all NENs and approximately 2% of all
gallbladder cancers [1,2]. Among all NENs originating in
the gallbladder, large-cell neuroendocrine carcinoma
(LCNEC) is exceedingly rare, and the first case world-
wide was reported in 2000 [3]. To date, although several
case reports of gallbladder LCNEC have been published
[3-16] (Table 1), its biological behavior, the appropriate
treatment modalities, and the overall patient prognosis
remain largely unclear. Herein, we report a rare case of
gallbladder LCNEC and present a brief literature review* Correspondence: surgerypumch@sina.com
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unless otherwise stated.to contribute to the increased understanding of the clin-
ical features of this disease.Case presentation
A 63-year-old woman came to our emergency room on
14 July 2013, with a history of intermittent right upper
quadrant pain that began 3 months prior. Ultrasound in-
dicated no other anomalies, except for a focal thickening
of the gallbladder wall. Computed tomography (CT)
showed a suspected mass measuring 0.6 × 0.3 cm on the
gallbladder plica (Figure 1a). Because she had a past
medical history of cholecystitis, we could not clearly deter-
mine whether the mass was a tumor or only thickened
mucosa; thus, watchful follow-up was recommended to
the patient. On the 29th of October 2013, the patient
returned to our clinic, and CT scan revealed a 2.0 ×
1.8 cm quasi-circular tumor located on the body of the
gallbladder in the same location as the mass detected
3.5 months earlier, with significant enhancement in the
portal venous phase (Figure 1b). The results of laboratory
tests, including tests for tumor markers and hormonal
profiles, were all within normal limits.
Laparoscopic cholecystectomy was performed, and an
intraoperative frozen pathological section indicated that
the lesion was malignant. Immediately thereafter, openis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological features of 17 cases of large-cell neuroendocrine carcinoma of the gallbladder






Metastasis Other component Treatments Prognosis, follow-up
(month)
1 Papotti et al. [3] M/50 Unclear Unclear <1 - - AC Cho DFS, 12
2 Papotti et al. [3] M/65 Unclear Fundus 2.5 - Liver - Cho Died, 14
3 Jun et al. [4] M/55 AP, jaundice Unclear Unclear Unclear Lymph node - Needle biopsy, Che Died, 1
4 Jun et al. [4] F/67 AP Unclear Huge + Lymph node - Needle biopsy, Che Died, 10
5 Noske and Pahl [5] F/81 AP, jaundice Neck 5 + Bone Adenosquamous Palliative surgery Unknown
6 Oshiro et al. [6] F/55 Back pain, fever Body 4.9 - - AC, SCNEC Radical Cho DFS, 20
7 Shimono et al. [7] F/64 AP Unclear 11.5 + - - Che, Rad, extended
hepatectomy
DFS, 36
8 Iype et al. [8] M/85 Anorexia,
weight loss
Fundus 1.5 - Unclear AC Cho, Che Died, 21
9 Lin et al. [9] F/65 Cushing’s
syndrome
Body Unclear - - -(ACTH-producing) Radical Cho, Che Died, 2
10 Sato et al. [10] F/68 Negative Fundus 3 + Lymph node AC Cho, extended
hepatectomy
DFS, 12





M/45 AP, jaundice Fundus 5.7 + Unclear AC Cho, Che Unknown
13 Okuyam et al. [13] M/64 Abdominal
fullness
Fundus 2.5 + Lymph node - Biopsy, Che Died, 22
14 Nakagawa et al. [14] M/56 Exophthalmos Unclear 9 + Multiple AC Che, Rad Died, 36
15 Meguro et al. [15] F/54 Negative Unclear Unclear - - AC Cho, extrahepatic bile duct
resection
DFS, 24
16 Russo et al. [16] M/59 AP Body 4 + Lymph node Mucinous carcinoma Radical Cho Unknown
17 Current study, 2014 F/63 AP, fever Body 2.0 - - AC Radical Cho DFS, 12














Figure 1 A fast-growing tumor located on the body of the
gallbladder. (a) Computed tomography showed a suspected mass,
measuring 0.6 cm, on the gallbladder plica 3.5 months prior. (b) At
admission 3.5 months later, CT showed a 2.0 × 1.8 cm quasi-circular
mass located on the body of gallbladder, with significant enhancement
in the portal venous phase.
Liu et al. World Journal of Surgical Oncology  (2015) 13:114 Page 3 of 5radical cholecystectomy with resection of a wedge of the
liver and the hepatoduodenal lymph nodes was performed.
The gross specimen showed a cauliflower-shaped mass,
and microscopically, the tumor consisted of the following
two components: moderately differentiated adenocarcin-
oma and poorly differentiated large-cell neuroendocrine
carcinoma (Figure 2a,b). Immunohistochemically, the neu-
roendocrine cells exhibited the strong expression of the
neuroendocrine markers chromogranin A (Figure 2c) and
synaptophysin (Figure 2d). In addition, these neuroendo-
crine cells showed a Ki67 index of over 80%. There was no
evidence of serous or liver invasion or lymph node or
distant metastasis. Thus, this lesion was assigned a final
classification of pT2N0M0 stage II, according to the
Union Internationale Contre le Cancer guidelines. The
postoperative course of this patient was uneventful, and
the carcinoma did not recur during a 12-month follow-
up period.The present case report is in compliance with the
Helsinki Declaration and has been approved by ethics
committee of Peking Union Medical College Hospital.
Discussion
According to the latest World Health Organization
(WHO) classification published in 2010 [17], NENs are
classified into the following four general categories that
are mainly based on mitotic count and the Ki67 prolifera-
tion index: (1) well differentiated neuroendocrine tumor
(NET) or grade 1 tumor, with a mitotic count of <2/10 per
high-power fields (HPF) and a Ki67 of ≤2%, such as a typ-
ical carcinoids; (2) intermediate differentiated NET or
grade 2 tumor, with a mitotic count of between 2 and 20/
10 HPF and a Ki67 of 3% to 20%, such as an atypical carci-
noids; (3) poorly differentiated neuroendocrine carcinoma
(NEC) or grade 3 tumor, with a mitotic count of >20/10
HPF and a Ki67 of >20%, which includes small-cell and
large-cell NECs; and (4) mixed adenoneuroendocrine car-
cinoma (MANEC), histologically exhibiting concomitant
adenocarcinoma (or other components) and NEC con-
comitantly. Primary gallbladder small-cell NEC (GB-
SCNEC) is particularly rare, with only 74 cases described
until 2011 [18]. Large-cell neuroendocrine carcinoma of
the gallbladder (GB-LCNEC) is exceedingly rare and was
first reported by Papotti in 2000 [3]. The histological fea-
tures of LCNEC are as follows: (1) positivity for neuroen-
docrine markers, among which chromogranin A and
synaptophysin are the most commonly identified; (2) a mi-
totic count exceeding 20/10 HPFs or a Ki67 index of over
20%; and (3) a specific NET pattern of an organoid struc-
ture, rosette formation, palisading, and trabecular arrange-
ment, as well as prominent nuclei that are over three
times the diameter of a lymphocyte. Although more than
ten cases of GB-LCNEC have been reported in the English
literature to date (Table 1), there is a paucity of data on
this tumor type.
We reviewed a series of 17 GB-LCNECs, including 16
previously reported cases and our present case. This series
of GB-LCNECs included reports of 6 (35%) pure LCNECs
and 11 (65%) LCNECs combined with other histological
components, including 9 concomitant with adeno-, one
with adenosquamous-, and one with mucinous carcinoma.
Patients with mixed histological components were classi-
fied as having MANEC according to the WHO 2010 classi-
fication [17]. Only one tumor was found to be a functional
ACTH-producing tumor in this series.
Enterochromaffin cells, the precursor cells of NENs, are
distributed throughout the gastrointestinal tract, bronchus,
endocrine glands, and skin. These are also common sites of
NEN. The gallbladder mucosa in the fundus and body is
devoid of neuroendocrine cells, which may appear after in-
testinal metaplasia due to chronic inflammation. This fact
explains why NENs rarely occur in the gallbladder. Virtually
Figure 2 Pathologically demonstrated mixed large-cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder. (a) A low-power
view (H&E, 100×) demonstrating the combination of a majority of poorly differentiated large cell neuroendocrine carcinoma (LCNEC) cells and
a minority of moderately differentiated adenocarcinoma cells (right lower quadrant). (b) A high-power view (H&E, 400×) demonstrating that
the neuroendocrine carcinoma cells were large in size, polygonal, and contained high numbers of mitotic figures. (c) Immunohistochemical
staining showing that the LCNEC cells were positive for chromogranin A. (d) Immunohistochemical staining showing that the LCNEC cells
were positive for synaptophysin.
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coexisting gallstones and chronic cholecystitis [19]. Our
patient presented non-specific vague abdominal pain in
the right upper quadrant, which is a typical symptom of
cholelithasis and should be considered a pathogenic
basis of NEC.
Similar to most previously reported cases of NEC, the
clinical symptoms and radiological findings of our patient
were nonspecific. According to the descriptions of the
series of 17 GB-LCNECs, abdominal pain (8/17, 47%) was
the most common symptom. Other symptoms, including
fever, jaundice, and weight loss, were also nonspecific.
SCNEC and LCNEC were confirmed to be genetically
similar and distinct from well-differentiated NETs [20].
LCNEC was thought to exhibit similar aggressive behavior
and early metastasis compared with SCNEC [4]. Among
the 17 GB-LCNECs described, nine (53%) were diagnosed
with direct hepatic invasion, and eight (47%) were identi-
fied with metastasis in the lymph nodes, liver, or bone.
Fortunately, our case showed no signs of liver invasion or
distant metastasis, which may have been attributed to
early detection.
Surgical resection, which has been determined to im-
prove the prognosis of patients with NEC [21], is consid-
ered to be the main treatment for gallbladder NECs. The
prognosis is very poor for patients with unresectable
masses [22], although multimodal treatments, including
chemotherapy and radiation therapy, have achieved goodresponses in some reports [7]. Follow-up results were re-
ported for 13 of the 17. Among them, seven (54%) died of
the disease in a median time of 14 months, while the other
six patients exhibited disease-free survival (DFS) after 12
to 36 months of follow-up. Four surviving patients had
some similar characteristics, such as small tumor size and
no liver invasion or metastasis, and they had undergone
radical surgery. The other two successful treatments for
patients with liver invasion or lymph node metastasis
mainly rely on extended surgery with hepatectomy and
lymph node dissection. The presence of the adenocarcin-
oma phenotype is thought to indicate poor prognosis [2].
However, we could not make a similar conclusion accord-
ing to this series of the 17 GB-LCNECs.Conclusions
LCNEC of the gall bladder is extremely rare and is usually
present along with other carcinoma types, such as adeno-
carcinoma, as determined histologically. The patient prog-
nosis is poor overall, but early detection with complete
resection may result in a relatively good prognosis.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the editor of this journal.
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